Peritoneal Mesothelioma
Peritoneal mesothelioma is a rare and aggressive cancer linked to asbestos exposure. A promising option for treating the cancer includes cytoreductive surgery (CRS) with heated chemotherapy (HIPEC). A new article explains cytoreductive surgery and HIPEC for the treatment of peritoneal mesothelioma. Cytoreductive surgery removes as many tumors as possible. In the case of peritoneal mesothelioma,…
A mesothelioma diagnosis is hard to receive and can be very overwhelming. Different research outcomes can help doctors and patients make better decisions though. One area of research is blood-based biomarkers. Two biomarkers that can help monitor mesothelioma include mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor mesothelioma progression. A new article…
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos, mainly affects the pleura, the lining of the lungs. It also affects the peritoneum, which is the lining of the abdomen. It is very tough to diagnose mesothelioma, which leads to underdiagnosis of the disease. A study in Brazil’s Sao Paulo State Hospital Cancer Registry looked…
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Researchers are studying the effectiveness of a multimodal treatment for peritoneal mesothelioma. The therapy involves cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC. Peritoneal mesothelioma is cancer of the abdominal lining. It is caused by inhaled or ingested asbestos fibers that travel to the lining of the abdomen. Over time, these fibers cause DNA changes…
PIPAC, or pressurized intraperitoneal aerosol chemotherapy, is showing promising results for mesothelioma, but patients don’t finish all their sessions. This is a problem because the patients then limit the effectiveness of their treatment. Researchers in France decided to figure out why patients are quitting their treatments early. Mesothelioma is a rare cancer mainly caused by…
Improvements have been made for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This treatment combination is typically performed on people with cancers in the abdominal region. One such cancer is peritoneal mesothelioma. Peritoneal mesothelioma is a cancer of the lining of the abdomen caused by asbestos exposure. Peritoneal mesothelioma is second to pleural mesothelioma in…
A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal that affects other cells. When…
Patients with thoracic and abdominal mesothelioma can extend survival when they are given aggressive surgery. This news came from a study at Baylor College of Medicine in Houston. When patients are given bicavity cytoreductive surgery, they had a median survival of 58.2 months. The results were published in December in the Journal of Thoracic and…
It is best to treat peritoneal mesothelioma as soon as possible. Waiting to receive treatment could prevent a patient from living longer than possible. Information from a study looking at treatment start times was published in the Journal of Gastrointestinal Surgery in November. Researchers observed patients who either received treatment quickly, had a delay in…
